Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial

Introduction Bamlanivimab and etesevimab (BAM + ETE) are monoclonal antibodies (mAbs) effective in reducing COVID-19-related hospitalizations and all-cause mortality in adult participants at increased risk for severe disease. We present pharmacokinetic (PK), efficacy, and safety results from pediatr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Infectious diseases and therapy 2023-07, Vol.12 (7), p.1861-1873
Hauptverfasser:	Upadhyaya, Himanshu P., Chien, Jenny Y., Long, Amanda J., Bohm, Martin S., Kallewaard, Nicole L., Macpherson, Lisa F., Patel, Dipak R., Hufford, Matthew M., Krull, Constance J., Ang, Jocelyn Y., Chen, Peter, Muller, William J., Potts, Jeffrey A., Quinn, Timothy, Williams, Mark
Format:	Artikel
Sprache:	eng
Schlagworte:	Adults Bamlanivimab Clinical trials COVID-19 Etesevimab Health aspects Infectious Diseases Internal Medicine Iran Labels Medicine Medicine & Public Health Monoclonal antibodies Mortality NCT NCT04427501 Original Research Pediatric Pediatrics Pharmaceutical industry Pharmacokinetics Product development Risk factors Safety Severe acute respiratory syndrome coronavirus 2 United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Introduction Bamlanivimab and etesevimab (BAM + ETE) are monoclonal antibodies (mAbs) effective in reducing COVID-19-related hospitalizations and all-cause mortality in adult participants at increased risk for severe disease. We present pharmacokinetic (PK), efficacy, and safety results from pediatric participants ( 12 to
ISSN:	2193-8229 2193-6382
DOI:	10.1007/s40121-023-00832-y